BiotechTube
Home/Tasman Therapeutics/Dan Browne
DB

Dan Browne

Chief Executive Officer

Tasman Therapeutics

Therapeutic Areas

PsychiatryTreatment-Resistant DepressionMood Disorders

Tasman Therapeutics Pipeline

DrugIndicationPhase
R-107Treatment-Resistant Depression (TRD)Phase 3

Leadership Team at Tasman Therapeutics

DP
Dr. Peter Surman
Chief Scientific Officer
LC
Lisa Craigie
Chief Legal and Commercial Officer
KD
Kent Durbin
Chief Financial Officer
PP
Professor Paul Glue
Clinical Advisory Board Chair & Chief Medical Officer
View full Tasman Therapeutics profile